We assessed similarities and differences in the electrographic signatures of local field potentials (LFPs) evoked by different pharmacological agents in zebrafish larvae. We then compared and contrasted these characteristics with what is known from electrophysiological studies of seizures and epilepsy in mammals, including humans. Ultimately, our aim was to phenotype neurophysiological features of drug-induced seizures in larval zebrafish for expanding knowledge on the translational potential of this valuable alternative to mammalian models. LFPs were recorded from the midbrain of 4-d-old zebrafish larvae exposed to a pharmacologically diverse panel of seizurogenic compounds, and the outputs of these recordings were assessed using frequency domain analysis. This included analysis of changes occurring within various spectral frequency bands of relevance to mammalian CNS circuit pathophysiology. From these analyses, there were clear differences in the frequency spectra of drug-exposed LFPs, relative to controls, many of which shared notable similarities with the signatures exhibited by mammalian CNS circuits. These similarities included the presence of specific frequency components comparable to those observed in mammalian studies of seizures and epilepsy. Collectively, the data presented provide important information to support the value of larval zebrafish as an alternative model for the study of seizures and epilepsy. These data also provide further insight into the electrophysiological characteristics of seizures generated in nonmammalian species by the action of neuroactive drugs.

Abstract
Drug development is a highly resource intensive process that uses large numbers of animals for assessing the safety and efficacy of drugs prior to clinical testing. Improving the efficiency of drug development in terms of financial expenditure and number of animals used is therefore of utmost concern, not only to industry, but also to animal welfare organisations such as the NC3Rs. Poor efficiency in drug development largely stems from drug attrition, particularly attrition in the latter stages of the testing due to the large amount of resources expended at the point of failure. It is therefore imperative that deleterious off-target effects are identified as early as possible. However, typically, identification of seizure as a side-effect of drugs is performed in the later stages of development due to the highly intensive and low-throughput nature of seizure assays. At which point, if a compound fails, a large amount of resources have been squandered. There therefore exists a need for high-throughput and relatively inexpensive seizure liability assays that can be used early in drug development to prevent compounds destined for failure undergoing unnecessary resource intensive testing.
In this thesis we propose a refined approach using non-invasive imaging techniques in non-protected life stage zebrafish as a method for the detection of seizurogenic compounds early in drug development. In addition, we highlight its utility for elucidating the pharmacodynamics of compounds. In this study, a transgenic zebrafish line containing a GCaMP6s calcium sensor under the control of the pan-neuronal promoter elavl3 was used for functional profiling of compounds with varied pharmacologies. Light sheet microscopy was used to record fluorescent activity in three spatial dimensions over time (4-dimensions) from the zebrafish brain after exposure to forty-three different compounds with varied pharmacodynamics and seizure liability profiles. Hierarchical clustering was employed in order to assess if compounds with seizurogenic activity or similar pharmacodynamics elicited specific functional brain activity. It was found that compounds with dopaminergic and serotonergic mechanisms of action elicited highly specific and similar brain activity patterns and that non-seizurogenic drugs also clustered separately from seizurogenic ones. Subsequent analyses, focussed on the utilisation of machine learning techniques, developing a model that could be used to discriminate between compounds with and without potentially seizurogenic effects. It is clear, from the analyses presented here, that drugs do in fact elicit specific brain patterns in zebrafish and that these brain patterns are effectively detected using light sheet microscopy. This system is highly applicable for use within the drug industry and even in its relatively preliminary stages provided an accurate method of discriminating between compounds based on their physiological effects in zebrafish.